Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanadrel is an orally active antihypertensive agent classified as a postganglionic adrenergic neuron blocker. It is primarily used for the management of mild to moderately severe hypertension. Guanadrel acts by being taken up into sympathetic neurons via the norepinephrine transporter and gradually displacing norepinephrine from its storage sites in nerve endings. This displacement blocks the release of norepinephrine in response to sympathetic nerve stimulation, resulting in reduced arteriolar vasoconstriction and lower blood pressure, particularly blunting reflex increases in sympathetic tone that occur with positional changes. Guanadrel has a rapid onset of action and a half-life of about 10 hours, allowing for relatively quick dose titration and twice-daily dosing. It is generally well tolerated with fewer central nervous system side effects compared to methyldopa and less orthostatic dizziness than guanethidine[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanadrel.